Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 22:11:1338567.
doi: 10.3389/fmolb.2024.1338567. eCollection 2024.

Targeting host-specific metabolic pathways-opportunities and challenges for anti-infective therapy

Monika I Konaklieva  1 , Balbina J Plotkin  2
Affiliations
Review

Targeting host-specific metabolic pathways-opportunities and challenges for anti-infective therapy

Monika I Konaklieva et al. Front Mol Biosci. .

Abstract

Microorganisms can takeover critical metabolic pathways in host cells to fuel their replication. This interaction provides an opportunity to target host metabolic pathways, in addition to the pathogen-specific ones, in the development of antimicrobials. Host-directed therapy (HDT) is an emerging strategy of anti-infective therapy, which targets host cell metabolism utilized by facultative and obligate intracellular pathogens for entry, replication, egress or persistence of infected host cells. This review provides an overview of the host lipid metabolism and links it to the challenges in the development of HDTs for viral and bacterial infections, where pathogens are using important for the host lipid enzymes, or producing their own analogous of lecithin-cholesterol acyltransferase (LCAT) and lipoprotein lipase (LPL) thus interfering with the human host's lipid metabolism.

Keywords: LCAT; LPL; anti-infectives; drug development; host-directed therapy; intracellular pathogens; lipid enzymes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Exogenous Lipoprotein Pathway (figure modified from “Introduction to Lipids and lipoproteins”. K.R.Feingold, https://www.ncbi.nlm.nih.gov/books/NBK305896/).
FIGURE 2
FIGURE 2
Endogenous Lipoprotein Pathway (figure modified from “Introduction to Lipids and lipoproteins”, K.R.Feingold, https://www.ncbi.nlm.nih.gov/books/NBK305896/).
FIGURE 3
FIGURE 3
LCAT in HDL metabolism (figure modified from “Introduction to Lipids and lipoproteins”, K.R.Feingold, https://www.ncbi.nlm.nih.gov/books/NBK305896/).
FIGURE 4
FIGURE 4
Scaffolds of the small molecules currently identified as LCAT activators.
FIGURE 5
FIGURE 5
Cartoon of LCAT domains and the various areas of binding of Compound A (1, Figure 4), and DS compounds, e.g., 6, (Figure 4), with Cys31 near the active site and Met49/Tyr51 of the lid, respectively. The active sites of many lipases are contained in the N-terminal domain and controlled by a so-called lid. The catalytic triad, Ser-Asp-His, is at the bottom of lid’s crevice (Berton et al., 2007). The lid domain covers the active site to control both enzyme activation and substrate specificity.
FIGURE 6
FIGURE 6
Scaffolds of the small molecules currently identified as LPL activators.
FIGURE 7
FIGURE 7
Bacterial molecular targets in the lipid metabolic pathways of the host (Figure 3) and their effects on lipid metabolism.
FIGURE 8
FIGURE 8
Structures of drugs affecting the cholesterol levels approved by the FDA for CVD-alternative illnesses; Nevirapine as anti-HIV treatment and Tofacitinib for treatment of rheumatoid arthritis, that have a favorable effect in increasing ApoA-I and reducing cholesterol ester catabolism, respectively.
FIGURE 9
FIGURE 9
Tetrahydrolipstatin (a representative of statin class of drugs), with the lactone ring as the electrophile responsible for its activity boxed. Lipstatin, a product of Streptomyces toxytricini mold inhibits mammalian lipases. Tetrahydrolipstatin (Orlistat), an FDA approved drug synthesized from lipstatin, binds to lipases in the gastrointestinal tract, thus blocking the digestion of dietary triacylglycerols.
See this image and copyright information in PMC

References

    1. Ahsan L., Ossoli A. F., Freeman L. A., Vaisman B., Amar M. J., Shamburek R. D., et al. (2014). Role of lecithin: cholesterol acyltransferase in HDL metabolism and atherosclerosis, in The HDL Handbook: biological functions and clinical implications. Komoda. T. ed. 2nd Edn. London: Academic Press, 159–194.
    1. Akesson L. S., Burnett J. R., Mehta D. K., Martin A. C. (2016). Lipoprotein lipase deficiency presenting with neonatal perianal abscesses. Bmj Case Rep. 2016, bcr2015212587. 10.1136/bcr-2015-212587 - DOI - PMC - PubMed
    1. Alekseeva L., Rault L., Almeida S., Legembre P., Edmond V., Azevedo V., et al. (2013). Staphylococcus aureus-induced G2/M phase transition delay in host epithelial cells increases bacterial infective efficiency. PLoS ONE 8, e63279. 10.1371/journal.pone.0063279 - DOI - PMC - PubMed
    1. Allen P. E., Martinez. J. J. (2020). Modulation of host lipid pathways by pathogenic intracellular bacteria. Pathogens 9 (8), 614. 10.3390/pathogens9080614 - DOI - PMC - PubMed
    1. Amar M. J. A., Sakurai T., Sakurai-Ikuta A., Sviridov D., Freeman L., Ahsan L., et al. (2015). A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E–knockout mice. J. Pharmacol. Exp. Ther. 352, 227–235. 10.1124/jpet.114.220418 - DOI - PMC - PubMed